Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Locally Advanced Unresectable Gastric Adenocarcinoma Clear all
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, oxaliplatin, capecitabine, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Monterey, California • Fairway, Kansas • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 22, 2026, 3:53 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil, Ramucirumab, Paclitaxel, Irinotecan, Capecitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
13
States / cities
Orange, California • Santa Monica, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, carboplatin, epirubicin hydrochloride
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
3
States / cities
Bethesda, Maryland • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced May 22, 2026, 3:53 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Bryostatin-1, Paclitaxel (Taxol)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced May 22, 2026, 3:53 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Interventions
CYNK-101, Pembrolizumab, Trastuzumab, Recombinant Human Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
106
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced May 22, 2026, 3:53 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Azenosertib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 3:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
Interventions
SKB264
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Interventions
5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab
Drug · Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 22, 2026, 3:53 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Interventions
Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 3:53 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
Interventions
ladiratuzumab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
27
States / cities
Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced May 22, 2026, 3:53 AM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 3:53 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
Interventions
STAR0602
Drug
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Loma Linda, California • Sacramento, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced May 22, 2026, 3:53 AM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Futibatinib, Magnetic Resonance Imaging, Paclitaxel, Ramucirumab
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Chicago, Illinois • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced May 22, 2026, 3:53 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Chandler, Arizona • Los Alamitos, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Ramucirumab, Paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced May 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Interventions
Ipilimumab, Best Supportive care (BSC)
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Miami Beach, Florida • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced May 22, 2026, 3:53 AM EDT